Multiplex real-time RT-PCR for prospective evaluation of WT1 and fusion gene transcripts in newly diagnosed de novo acute myeloid leukemia

Leukemia & Lymphoma
Masamitsu YanadaIsamu Sugiura

Abstract

Prognostic assessment is crucial for the management of AML. Although the use of karyotype analysis for risk-stratification is widely accepted, prognosis of AML remains ambiguous, particularly for patients categorized into the intermediate cytogenetic risk group and additional markers are required for an accurate prediction of outcome. For this study, we used multiplex real-time RT-PCR, which can simultaneously quantify WT1 and 10 distinct fusion gene transcripts, to prospectively evaluate the pre-treatment bone marrow findings of 53 de novo AML patients. Five patients with normal karyotype or insufficient metaphases detected by conventional karyotype analysis proved to have AML1-MTG8, CBFbeta-MYH11 or PML-RARalpha fusion transcripts. WT1 overexpression was observed in 92% of the patients, and the levels were significantly higher in the cytogenetic favorable risk group, especially patients with PML-RARalpha. WT1 levels also correlated with the percentage of blasts in bone marrow, especially in cases of core-binding factor leukemia. There was no association between initial WT1 levels and outcome in terms of event-free survival or overall survival. These results suggest that multiplex real-time RT-PCR is rapid and useful for the p...Continue Reading

References

Mar 4, 2000·Nature Genetics·U ScherfJ N Weinstein
Mar 5, 2003·Leukemia & Lymphoma·Kazuoki OsumiTomoki Naoe

❮ Previous
Next ❯

Citations

Jan 29, 2011·Annals of Hematology·Alexandar TzankovUrsula Günthert
Apr 9, 2010·International Journal of Hematology·Yuho NajimaHisashi Sakamaki
Dec 18, 2007·European Journal of Haematology·Mauri M HämäläinenTarja-Terttu Pelliniemi
Dec 17, 2009·Hematological Oncology·Carolyn OwenPeter Paschka
Jun 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter PaschkaClara D Bloomfield
Aug 3, 2006·Pediatric Blood & Cancer·Patricia C RodriguesJosé A Yunes
May 26, 2007·Expert Reviews in Molecular Medicine·Suzie Ariyaratana, David M Loeb
Jan 27, 2019·Journal of Clinical Medicine·Ghazala Naz KhanBarbara-Ann Guinn
Nov 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jochen GreinerMichael Schmitt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.